Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H3 | Q13133 | 7/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 4/20 | 0.46 |
| ▸ | CASP6 | P55212 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.42 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.42 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.42 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20523720 | 0.85 | KMT2A (0.43) | NR1H3KMT2ASCN2ANR1H2CASP6 | |
| SCHEMBL20523677 | 0.79 | TYMS (0.42) | NR1H3KMT2AMEN1SCN2ANR1H2 | |
| SCHEMBL30758650 | 0.74 | KMT2A (0.76) | NR1H3KMT2AMEN1SCN2ANR1H2 | |
| SCHEMBL29168849 | 0.74 | KMT2A (0.76) | NR1H3KMT2AMEN1SCN2ANR1H2 | |
| SCHEMBL6679321 | 0.74 | KMT2A (0.54) | NR1H3KMT2AMEN1SCN2ANR1H2 | |
| SCHEMBL31342202 | 0.72 | NR1H3 (0.48) | NR1H3KMT2AMEN1SCN2ANR1H2 | |
| SCHEMBL6968611 | 0.71 | G6PD (0.59) | NR1H3KMT2AMEN1SCN2ANR1H2 | |
| SCHEMBL11808285 | 0.71 | ESR1 (0.72) | NR1H3KMT2AMEN1SCN2ANR1H2 | |
| SCHEMBL6392226 | 0.71 | SCN2A (0.66) | NR1H3KMT2AMEN1SCN2ANR1H2 | |
| SCHEMBL27712799 | 0.71 | KMT2A (0.53) | NR1H3KMT2AMEN1SCN2ANR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11135209-B2 | Compositions and methods for inhibiting protein kinases | UNIVERSITY OF HOUSTON SYSTEM (US) | 2021-10-05 | — | — | US | disclosed |
| EP-3600307-B1 | COMPOSITIONS FOR USE IN METHODS OF INHIBITING PROTEIN KINASES | UNIV HOUSTON SYSTEM (US) | 2021-05-05 | — | — | EP | disclosed |
| EP-3600307-A1 | COMPOSITIONS FOR USE IN METHODS OF INHIBITING PROTEIN KINASES | University of Houston System (US) | 2020-02-05 | — | — | EP | disclosed |
| US-20200030303-A1 | COMPOSITIONS AND METHODS FOR INHIBITING PROTEIN KINASES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2020-01-30 | — | — | US | disclosed |
| WO-2018183633-A1 | COMPOSITIONS FOR USE IN METHODS OF INHIBITING PROTEIN KINASES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2018-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11135209-B2 | Compositions and methods for inhibiting protein kinases | RIPK2, RIPK1, NOD2 | NR1H3 3463/4885KMT2A 3666/4885MEN1 2285/4885 |
| US-20200030303-A1 | COMPOSITIONS AND METHODS FOR INHIBITING PROTEIN KINASES | RIPK2, RIPK1, NOD2 | NR1H3 3463/4885KMT2A 3666/4885MEN1 2285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.